S0155 Sterile dilutant for epoprostenol, 50 ml

Name of the Procedure:

• Common Name: Sterile dilutant for epoprostenol
• Technical/Medical Term: HCPCS Code S0155

Summary

Sterile dilutant for epoprostenol is a sterile, 50 ml solution used to prepare the medication epoprostenol. This dilutant typically is used for patients with pulmonary arterial hypertension (PAH) to assist in administering the medication correctly.

Purpose

• Medical Conditions/Problems Addressed: Pulmonary arterial hypertension (PAH)
• Goals/Expected Outcomes: To properly dilute epoprostenol for safe and effective intravenous use, thereby helping to lower blood pressure in the lungs and improve symptoms associated with PAH.

Indications

• Specific Symptoms/Conditions: Shortness of breath, dizziness, fatigue, chest pain associated with PAH.
• Patient Criteria/Factors: Patients diagnosed with PAH who require continuous intravenous infusion therapy.

Preparation

• Pre-Procedure Instructions: No specific patient preparation is needed solely for the dilutant, but patients must follow their healthcare provider's instructions for the administration of epoprostenol.
• Diagnostic Tests/Assessments: Baseline assessments of heart and lung functions may be required.

Procedure Description

1. Preparation: Gather all necessary materials: sterile dilutant, epoprostenol medication, IV equipment.
2. Mixing: Use aseptic technique to mix the sterile dilutant with the epoprostenol powder according to prescribed instructions.
3. Administration: Administer the diluted medication intravenously as prescribed by the healthcare provider.
   • Tools/Equipment: Sterile dilutant, epoprostenol medication, mixing syringes or equipment, IV infusion pump.
   • Anesthesia/Sedation: Not applicable for the dilutant itself, but patient comfort measures should be managed per the infusion procedure.

Duration

The preparation of dilutant and medication typically takes about 10-15 minutes. The administration of epoprostenol is continuous and ongoing.

Setting

• Location: Hospital, outpatient clinic, home healthcare settings, or anywhere intravenous medication administration occurs.

Personnel

• Healthcare Professionals: Nurses, pharmacists, sometimes a physician overseeing the treatment, and possibly home healthcare providers.

Risks and Complications

• Common Risks: Risk of infection at the injection site, improper dilution leading to incorrect dosage administration.
• Possible Complications: Allergic reactions, local site reactions, or systemic issues if contamination occurs.

Benefits

• Expected Benefits: Accurate and effective delivery of epoprostenol to manage symptoms of PAH.
• Realization Timeline: Benefits are often seen promptly after initiation of proper treatment regimen.

Recovery

• Post-Procedure Care: Regular monitoring of infusion site, ensuring proper functioning of the IV pump.
• Expected Recovery Time: Continuous therapy; recovery or symptom management is ongoing and monitored regularly.
• Restrictions/Follow-Up: Follow-up appointments to monitor effectiveness and adjust dosages as needed.

Alternatives

• Other Treatment Options: Oral medication, other injectable treatments, inhaled therapies.
• Pros and Cons: Oral medications may be easier to take but less effective. Alternatives might have different side effects or efficacy rates.

Patient Experience

• During Procedure: Little to no discomfort during the preparation phase; however, patients might feel discomfort at the IV site.
• After Procedure: Regular maintenance and monitoring are necessary. Pain management involves ensuring proper site care and addressing any side effects from epoprostenol administration.